RT Journal Article SR Electronic T1 Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 6179 OP 6183 VO 36 IS 11 A1 ANTONIO GIORGIO A1 MARIA GABRIELLA MEROLA A1 LUCA MONTESARCHIO A1 FRANCESCA MEROLA A1 BRUNO SANTORO A1 CARMINE COPPOLA A1 PIETRO GATTI A1 FERDINANDO AMENDOLA A1 ANTONELLA DI SARNO A1 ANDREA CALVANESE A1 PAOLO MATTEUCCI A1 VALENTINA GIORGIO YR 2016 UL http://ar.iiarjournals.org/content/36/11/6179.abstract AB Aim: To compare in a randomized controlled trial (RCT) 3-year survival of cirrhotic patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT) treated with sorafenib plus percutaneous radiofrequency ablation (RFA) of both intraparenchymal HCC and PVTT (combination Group) or sorafenib alone (sorafenib-alone Group). Patients and Methods: Ninety-nine consecutive Child A cirrhotics were randomized to receive RFA of both HCC and main portal vein tumor thrombus (MPVTT) plus sorafenib (n=49) or sorafenib alone (n=50). Results: One-, 2- and 3-year survival rates were 60%, 35% and 26%, respectively, in the combination group and 37% and 0 % at 1- and 2-year, respectively, in the sorafenib alone group. At multivariate analysis, the combination of RFA of both HCC and MPVTT was the only factor predicting survival. Conclusion: Use of RFA of both HCC and MPVTT plus sorafenib significantly increases 3-year survival compared to sorafenib alone.